Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 4;11(8):1154.
doi: 10.3390/biom11081154.

Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review

Affiliations
Review

Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review

Agnieszka Chlebicz-Wójcik et al. Biomolecules. .

Abstract

Irritable bowel syndrome is not a life-threatening disease, yet it significantly affects the quality of life and contributes to economic loss. It is estimated that even up to 45% of the world's population can suffer from the disease. The first attempts to diagnose irritable bowel syndrome were made at the end of the 19th century; however, establishing appropriate diagnostic criteria and treatment methods is still ongoing. To date, little is known about the etiology of irritable bowel syndrome; however, growing attention is drawn to the intestinal microbiota as a factor in the disease development. For this reason, researchers have conducted many studies on therapies that modulate the microbiota, among which probiotics, prebiotics, and synbiotics are widely studied. To date, most studies have examined probiotics; however, there are also several studies demonstrating the efficacy of prebiotics and synbiotics. The aim of this review was to summarize findings on the usefulness of probiotics, prebiotics, and synbiotics in the treatment of irritable bowel syndrome.

Keywords: irritable bowel syndrome; prebiotics; probiotics; synbiotics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ford A.C., Sperber A.D., Corsetti M., Camilleri M. Irritable Bowel Syndrome. Lancet. 2020;396:1675–1688. doi: 10.1016/S0140-6736(20)31548-8. - DOI - PubMed
    1. Üçüncü M.Z., Çoruh Akyol B., Toprak D. The Early Diagnosis of Fibromyalgia in Irritable Bowel Syndrome Patients. Med. Hypotheses. 2020;143:110119. doi: 10.1016/j.mehy.2020.110119. - DOI - PubMed
    1. Hadjivasilis A., Tsioutis C., Michalinos A., Ntourakis D., Christodoulou D.K., Agouridis A.P. New Insights into Irritable Bowel Syndrome: From Pathophysiology to Treatment. Ann. Gastroenterol. 2019;32:1–11. doi: 10.20524/aog.2019.0428. - DOI - PMC - PubMed
    1. Mosińska P., Sałaga M. Clinical Features of Irritable Bowel Syndrome. In: Fichna J., editor. Introduction to Gastrointestinal Diseases. Volume 1. Springer; Cham, Switzerland: 2017. pp. 23–27.
    1. Ida M., Nishida A., Akiho H., Nakashima Y., Matsueda K., Fukudo S. Evaluation of the Irritable Bowel Syndrome Severity Index in Japanese Male Patients with Irritable Bowel Syndrome with Diarrhea. BioPsychoSoc. Med. 2017;11:7. doi: 10.1186/s13030-017-0092-x. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources